source
- Two Massachusetts biotech firms shut down, ending cancer and eye‑disease programsAdecto Pharmaceuticals, a Boston‑based biotech developing a treatment for cancers resistant to standard immunotherapy, announced it has ceased operations as of September 30. CEO Nora Minerva shared…
- Report highlights 20 women reshaping biopharma across oncology and rare disease fieldsThe 2026 special report spotlights twenty women who are driving change in biopharma, covering areas such as oncology and rare diseases. The series, now in its eighth year, has recognized over 160…